Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial oleh Thuy P. Nguyen, Quyet Do, Lan T. Phan, Duc V. Dinh, Hiep Khong, Luong V. Hoang, Thuong V. Nguyen, Hung N. Pham, Men V. Chu, Toan T. Nguyen, Quang D. Pham, Tri M. Le, Tuyen N.T. Trang, Thanh T. Dinh, Thuong V. Vo, Thao T. Vu, Quynh B.P. Nguyen, Vuong T. Phan, Luong V. Nguyen, Giang T. Nguyen, Phong M. Tran, Thuan D. Nghiem, Tien V. Tran, Tien G. Nguyen, Tuynh Q. Tran, Linh T. Nguyen, Anh T. Do, Dung D. Nguyen, Son A. Ho, Viet T. Nguyen, Dung T. Pham, Hieu B. Tran, Son T. Vu, Su X. Hoang, Trung M. Do, Xuan T. Nguyen, Giang Q. Le, Ton Tran, Thang M. Cao, Huy M. Dao, Thao T.T. Nguyen, Uyen Y Doan, Vy T.T. Le, Linh P. Tran, Ngoc M. Nguyen, Ngoc T. Nguyen, Hang T.T. Pham, Quan H. Nguyen, Hieu T. Nguyen, Hang L.K. Nguyen, Vinh T. Tran, Mai T.N. Tran, Truc T.T. Nguyen, Phat T. Ha, Hieu T. Huynh, Khanh D. Nguyen, Ung T. Thuan, Chung C. Doan, Si M. Do